African trypanosomiasis pathophysiology

African trypanosomiasis Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating African trypanosomiasis from other Diseases
Epidemiology and Demographics
Risk Factors
Natural History, Complications and Prognosis
Diagnosis
History and Symptoms
Physical Examination
Laboratory Findings
X Ray
CT Scan
MRI
Ultrasound
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
African trypanosomiasis pathophysiology On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of African trypanosomiasis pathophysiology All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on African trypanosomiasis pathophysiology
CDC on African trypanosomiasis pathophysiology
African trypanosomiasis pathophysiology in the news
Blogs on African trypanosomiasis pathophysiology
Directions to Hospitals Treating African trypanosomiasis
Risk calculators and risk factors for African trypanosomiasis pathophysiology

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-In-Chief: Pilar Almonacid

Pathophysiology

Two subspecies of Trypanosoma brucei. that are morphologically indistinguishable is responsible for African trypanosomiasis. They cause distinct disease patterns in humans: T. b. gambiense causes West African sleeping sickness and T. b. rhodesiense causes East African sleeping sickness. (A third member of the complex, T. b. brucei, under normal conditions does not infect humans.)

Stages of infection

• A trypanosomal chancre develops on the site of inoculation.
• This is followed by a hemolymphatic stage with symptoms that include fever, lymphadenopathy, and pruritus.
• In the meningoencephalitic stage, invasion of the central nervous system can cause headaches, somnolence, abnormal behavior, and lead to loss of consciousness and coma.
• The course of infection is much more acute with T. b. rhodesiense than T. b. gambiense.

Transmission

Infection is usually transmitted via the tsetse fly bite to the human host.

Incubation period

Clinical manifestations generally appear within 1–3 weeks of the infective bite for T. b. rhodesiense and months to years for T. b. gambiense.

Reservoir

• Humans are the main reservoir for Trypanosoma brucei gambiense, but this species can also be found in animals.
• Wild animals are the main reservoir of T. b. rhodesiense.

Human cycle

• During a blood meal on the mammalian host, an infected tsetse fly (genus Glossina) injects metacyclic trypomastigotes into skin tissue.
• The parasites enter the lymphatic system and pass into the bloodstream.
• Inside the host, the microbe transforms into bloodstream trypomastigotes
• They are carried to other sites throughout the body, reach other blood fluids (e.g., lymph, spinal fluid), and continue the replication by binary fission
• The entire life cycle of African Trypanosomes is represented by extracellular stages.

Tsetse fly cycle

• The tsetse fly becomes infected with bloodstream trypomastigotes when taking a blood meal on an infected mammalian host
• In the fly’s midgut, the parasites transform into procyclic trypomastigotes, multiply by binary fission
• Leave the midgut, and transform into epimastigotes
• The epimastigotes reach the fly’s salivary glands and continue multiplication by binary fission
• The cycle in the fly takes approximately 3 weeks.

Life cycle of Trypanosoma brucei gambiense and Trypanosoma brucei rhodesiense

Infective stage of the parasite

• Metacyclic trypomastigotes

Diagnostic stage of the parasite

• Bloodstream trypomastigotes

Pathogenesis

• Trypomastigotes have proteins on their surface known as major variant surface glycoprotein (VSG). Approximately 10 million copies of a single VSG present on each trypomastigotes.
• Once inside the host they undergo antigenic variation.
• This VSG antigenic variation leads to nonspecific polyclonal B cell activation
• Immunoglobulin M is produced in large quantities in response to B cell activation
• Immune complexes form and secondary hyperplasia of the reticuloendothelial system occurs.
• This process may lead to downregulation of the immune system.

Immune response

• Tumor necrosis factor α (TNF-α) produces on activation of cell mediated immunity, stimulates T lymphocytes and macrophages, which help in eliminating intracellular brucellae. Virulent brucellae tend to suppress the activity of tumor necrosis factor α (TNF-α) and IFN-gamma.
• Cytokines such as interleukin (IL) 12 promote production of Interferon γ (IFN-γ) responses. IFN-γ, which drives TH1-type responses and stimulates macrophage activation. Cytokines, which include , IL-6, IL-4and IL-10, down-regulate the protective response.